Print this page
-
Pediatric Acute Leukemia (PedAL) Screening Trial: Developing New Therapies for Relapsed Leukemias.
Protocol: 112204Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Leukemia, not otherwise specified -
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma.
Protocol: 112305Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Hodgkin's Lymphoma -
A Phase 2 Study of Blinatumomab in Combination with Chemotherapy for Infants with Newly Diagnosed Acute Lymphoblastic Leukemia with Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax.
Protocol: 112507Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Lymphoid Leukemia -
An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia.
Protocol: 112510Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Leukemia, other -
A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL).
Protocol: 112512Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Lymphoid Leukemia -
Collection of Plasma Samples Using Sodium Heparin from Subjects Undergoing Intravenous Busulfan Treatment.
Protocol: 112514Applicable Disease Sites: Heart, Cardiovascular, and Non-Cancerous Blood Disorders
Leukemia, not otherwise specified
Myeloid and Monocytic Leukemia -
A Phase 2 Study of Blinatumomab in Combination with Chemotherapy for Infants with Newly Diagnosed Acute Lymphoblastic Leukemia with Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax.
Protocol: 112507Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Lymphoid Leukemia -
A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Asciminib in Pediatric Participants Newly Diagnosed or Previously Treated with Philadelphia-Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without Known T315I Mutation.
Protocol: 112601Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Leukemia, not otherwise specified
Leukemia, other -
An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia.
Protocol: 112510Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Leukemia, other -
Characterizing Lymphoma Survivors Experiences, Needs, and Preferences During the Transition to Cancer Survivorship: The Survivor Health Check Program Development Trial.
Protocol: 132203Principal Investigator:
- Sharon Manne
Applicable Disease Sites: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
A Phase II Study of Daratumumab-Hyaluronidase for Chemotherapy-Relapsed/Refractory Minimal Residual Disease (MRD) in T Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/T-LBL).
Protocol: 112512Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Lymphoid Leukemia -
Collection of Plasma Samples Using Sodium Heparin from Subjects Undergoing Intravenous Busulfan Treatment.
Protocol: 112514Applicable Disease Sites: Heart, Cardiovascular, and Non-Cancerous Blood Disorders
Leukemia, not otherwise specified
Myeloid and Monocytic Leukemia -
A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Asciminib in Pediatric Participants Newly Diagnosed or Previously Treated with Philadelphia-Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without Known T315I Mutation.
Protocol: 112601Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Leukemia, not otherwise specified
Leukemia, other -
Characterizing Lymphoma Survivors Experiences, Needs, and Preferences During the Transition to Cancer Survivorship: The Survivor Health Check Program Development Trial.
Protocol: 132203Principal Investigator:
- Sharon Manne
Applicable Disease Sites: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma